Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04400383
Recruitment Status : Recruiting
First Posted : May 22, 2020
Last Update Posted : June 11, 2020
Sponsor:
Collaborator:
Shanghai East Hospital
Information provided by (Responsible Party):
Carsgen Therapeutics, Ltd.

Brief Summary:
This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.

Condition or disease Intervention/treatment Phase
Solid Tumor Gastric Cancer Pancreatic Adenocarcinoma Drug: AB011 Injection Phase 1

Detailed Description:
This study is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors. The study is composed of two stages: stage I is for dose escalation and stage II is for dose expansion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 103 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open, Two-stage, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
Actual Study Start Date : June 4, 2020
Estimated Primary Completion Date : May 3, 2022
Estimated Study Completion Date : June 1, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: AB011 Injection
AB011 Injection treatment. This phase 1 trial will include two stages, a dose escalation stage and an expansion stage.
Drug: AB011 Injection
AB011 Injection with dose escalation stage of 1mg/kg up to 40mg/kg, as well as dose expansion stage with recommended dose level from dose escalation stage.
Other Names:
  • recombinant humanized anti-Claudin 18.2 monoclonal antibody injection
  • recombinant humanized anti-CLDN 18.2 monoclonal antibody injection




Primary Outcome Measures :
  1. Incidence of adverse events (AE) of single and multiple dose (according to NCI CTCAE 5.0) [ Time Frame: up to 8 months ]
    An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

  2. Incidence of serious adverse events (SAE) of single and multiple dose (according to NCI CTCAE 5.0) [ Time Frame: up to 8 months ]
    An adverse event is any undesirable experience associated with the use of a medical product in a patient. The event is serious when the patient outcome is: Death; Life-threatening; Hospitalization (initial or prolonged); Disability or Permanent Damage; Congenital Anomaly/Birth Defect; Other Serious (Important Medical Events).

  3. The incidence and case number of DLT (Dose Limiting Toxicity) during observation period [ Time Frame: up to 28 days ]
    DLT is short for Dose Limiting Toxicity. dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.

  4. Recommended Phase 2 Dose (RP2D) [ Time Frame: Up to 1 Cycle after the last participant is enrolled in dose expansion phase (Approximately 2 years) ]
    The RP2D will be determined during the dose expansion stage of the study. RP2D will be determined using available safety and efficacy data.


Secondary Outcome Measures :
  1. Pharmacokinetics: Area Under Curve (AUC) with immunoanalytical method [ Time Frame: Up to 28 days after injection ]
    AUC will be recorded from the PK serum samples collected.

  2. Pharmacokinetics: plasma clearance rate (CL) with immunoanalytical method [ Time Frame: Up to 28 days after injection ]
    CL will be recorded from the PK serum samples collected.

  3. Pharmacokinetics: minimum concentration (Cmin) with immunoanalytical method [ Time Frame: Up to 28 days after injection ]
    Cmin will be recorded from the PK serum samples collected.

  4. Pharmacokinetics: maximum concentration (Cmax) with immunoanalytical method [ Time Frame: Up to 28 days after injection ]
    Cmax will be recorded from the PK serum samples collected.

  5. Pharmacokinetics: half-life (T1/2) with immunoanalytical method [ Time Frame: Up to 28 days after injection ]
    T1/2 will be recorded from the PK serum samples collected.

  6. Pharmacokinetics: apparent volume of distribution (Vd) with immunoanalytical method [ Time Frame: Up to 28 days after injection ]
    Vd will be recorded from the PK serum samples collected.

  7. Immunogenicity [ Time Frame: Up to 8 months (end of treatment) ]
    Incidence of anti-drug antibodies

  8. Efficacy: objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) [ Time Frame: Up to 8 months (end of treatment) ]
    The ORR is defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1.

  9. Efficacy: disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) [ Time Frame: Up to 8 months (end of treatment) ]
    The DCR is defined as the proportion of subjects with complete or partial objective response, or stable disease based on RECIST V1.1.

  10. Efficacy: duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) [ Time Frame: from the date of the first response CR/PR (whichever is first recorded) to the date of radiographical progression/death or date of censoring, up to 8 months. ]
    DOR is defined as the time from the date of the first response CR (complete remission)/PR (partial remission) (whichever is first recorded) to the date of radiographical progression/death or date of censoring.

  11. Efficacy: progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) [ Time Frame: from date of treatment start until the date of radiological disease progression or until death due to any cause, up to 8 months. ]
    PFS is defined as the time from date of treatment start until the date of radiological disease progression or until death due to any cause.

  12. Efficacy: overall survival (OS) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) [ Time Frame: from the date of treatment start until the documented date of death from any cause, up to 12 months. ]
    OS is defined as the time from the date of treatment start until the documented date of death from any causes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Aged 18 to 80 years, either sex;
  • 2. Patients with histologically or pathologically confirmed advanced solid tumors should have failed the standard treatment, or have no standard treatment regimen available, or have no access to standard treatment;
  • 3. Tumor tissue samples is CLDN18.2 positive detected by central laboratory;
  • 4. According to RECIST1.1, there are at least one evaluable tumor lesion during dose escalation period (period 1), and at least one measurable tumor lesion during dose expansion period (period 2);
  • 5. The ECOG score is 0 to 1;
  • 6. Expected survival > 3 months;
  • 7. Various organs in good condition;
  • 8. Fertile eligible patients (male and female) and their partners are willing to use a reliable method of contraception (hormones, barriers or abstinence) during the study and within 90 days after the last study treatment; women of childbearing potential must be tested for serum or urine pregnancy within 7 days before enrollment with negative results;
  • 9. Patients are informed of this study before the trial and sign written informed consent form.

Exclusion Criteria:

  • 1. Received anti-tumor therapies within 4 weeks prior to first administration of study drug, except: within 6 weeks for nitrosoureas or mitomycin C, within 2 weeks or 5 half-life of drugs (whichever longer) for oral fluorouracils and small molecular targeted drugs, and within 2 weeks for traditional Chinese medicines with indications of anti-tumor;
  • 2. Received other non-marketed clinical trial drugs within 4 weeks prior to first administration of study drugs;
  • 3. Received major surgery or had significant trauma within 4 weeks prior to first administration of study drug;
  • 4. Received systemic corticosteroids or other immunosuppressors within 14 days prior to first administration of study drug;
  • 5. Patients with AEs from previous treatment that have not recovered to CTCAE 5.0 ≤1;
  • 6. Patients have central nervous system (CNS) metastasis or meningeal metastasis, or other evidences which demonstrate the CNS metastasis or meningeal metastasis are not controlled, resulting that patients are not eligible for enrollment at the investigator's discretion;
  • 7. Patients with any active infection which requires systemic treatment with of anti-infection currently;
  • 8. Patients with medical history of immune deficiency;
  • 9. Patients with hepatitis B; with HCV infection;
  • 10. Patients have interstitial lung disease at present, or had medical history of interstitial lung disease;
  • 11. Patients have significant medical history of cardiovascular and cerebrovascular diseases;
  • 12. Have high risks of gastrointestinal hemorrhage at the investigator's discretion;
  • 13. Patients who need long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) ;
  • 14. Known alcohol use or drug dependence;
  • 15. Patients with mental disorders or poor compliance;
  • 16. Pregnant or lactating women;
  • 17. Patients have other serious systemic diseases or cannot participate in this trial due to other reasons, at the investigator's discretion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04400383


Contacts
Layout table for location contacts
Contact: Zonghai Li, Dr. 86-21-64355922 zonghaili@carsgen.com
Contact: Zaiwen Liu 86-17717520326 zaiwenliu@carsgen.com

Locations
Layout table for location information
China, Shanghai
Shanghai East Hospital Recruiting
Shanghai, Shanghai, China, 200123
Contact: Jin Li    8613761222111    lijin@csco.org.cn   
Sponsors and Collaborators
Carsgen Therapeutics, Ltd.
Shanghai East Hospital
Investigators
Layout table for investigator information
Principal Investigator: Jin Li Shanghai East Hospital
Layout table for additonal information
Responsible Party: Carsgen Therapeutics, Ltd.
ClinicalTrials.gov Identifier: NCT04400383    
Other Study ID Numbers: AB011-ST-01
First Posted: May 22, 2020    Key Record Dates
Last Update Posted: June 11, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Carsgen Therapeutics, Ltd.:
advanced solid tumors
Gastric Cancer
Esophagogastric Junction Cancer
Pancreatic Adenocarcinoma
Claudin 18.2
CLDN18.2
monoclonal antibody
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Stomach Neoplasms
Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Antineoplastic Agents, Immunological
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents